AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems
DeviceOther names: AtriClip FLEX (ACH2), AtriClip Long (LAA), AtriClip Standard (ACH1)
NCT Number: NCT02701062
Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to participate. Patients enrolled will be randomized 2:1 (2 with AtriClip to 1 without AtriClip. Subjects who develop Post-operative Atrial Fibrillation (POAF) and receive the AtriClip will be followed for 365 days post index procedure.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Sharp Memorial Hospital, San Diego, California, United States
Patients without a documented history of AF but who present with a CHA2DS2- VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category) of => 2 and HASBLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) of => 2 and will undergo a valve or CABG (structural heart) procedure with direct visual access to the LAA will be eligible to participate based upon the inclusion and exclusion criteria defined in this protocol. Up to 2000 patients will enroll at up to 40 sites and will be randomized 2:1 (2 with AtriClip to 1 without AtriClip. Subjects who not develop Post-operative Atrial Fibrillation (POAF) will be followed for 30 days for safety. Subjects who develop POAF and receive the AtriClip will be followed for 365 days post index procedure.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients satisfying the following criteria will be considered the screening population and will be eligible for participation:
Exclusion criteria
Patients satisfying the following criteria will not be eligible for participation:
Intra-Operative Exclusion Criteria
Other names: AtriClip FLEX (ACH2), AtriClip Long (LAA), AtriClip Standard (ACH1)
Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
Other names: Warfarin/Coumadin, New oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban
Time frame: Within any 24 hour period during the first 2 days post-index procedure
Defined as: stroke, major bleeding that requires re-operation and/or transfusion of > 2 U packed red blood cells (PRBC), myocardial infarction (MI), or death.
Time frame: Intraoperative period
Successful exclusion of LAA is defined as no (0 mm) flow between LAA and LA and < 5 mm LAA remnant by intraoperative TEE with Doppler.
Time frame: 365 days post index procedure
Events to be evaluated include: Thromboembolic & Hemorrhagic Events such as cerebrovascular accident (CVA), transient ischemic attack (TIA), peripheral ischemia, hemorrhagic stroke, neurologic bleed, gastrointestinal (GI) bleeds, or other major bleeding event.
Time frame: 30 days Post-Procedure
Events to be evaluated include: Thromboembolic & Hemorrhagic Events such as cerebrovascular accident (CVA), transient ischemic attack (TIA), peripheral ischemia, hemorrhagic stroke, neurologic bleed, gastrointestinal (GI) bleeds, or other major bleeding event.
Time frame: 365 Days Post-Procedure
Events to be evaluated include: Thromboembolic & Hemorrhagic Events such as cerebrovascular accident (CVA), transient ischemic attack (TIA), peripheral ischemia, hemorrhagic stroke, neurologic bleed, gastrointestinal (GI) bleeds, or other major bleeding event.
Time frame: 365 Days Post-Procedure
Healthcare resource utilization variance between groups as related to hospital length-of-stay (LOS) and hospital readmissions.
Time frame: 365 Days Post-Procedure
Healthcare resource utilization variance between groups as related to hospital length-of-stay (LOS) and hospital readmissions.
Time frame: 365 Days Post-Procedure
Specifically, reoperation for bleeding, neurologic consults for stroke or TIA, and emergency department (ED) visits.
AtriCure, Inc.
Industry
Acronym: ATLAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03779841
Post-operative Atrial Fibrillation
Stanford, California, United States
View Trial DetailsNCT03943927
Post-operative Atrial Fibrillation
Nashville, Tennessee, United States
View Trial DetailsNCT03525860
Acupuncture Therapy, Post-operative Atrial Fibrillation
Rochester, Minnesota, United States
View Trial DetailsNCT06958029
Arrhythmias, Cardiac, Atrial Fibrillation
Khon Kaen, Thailand
View Trial Details